Dr. Jill Stefanelli Joins illumiSonics as Advisory Board Member and Consultant in Digital and Molecular Pathology
April 6, 2023 – illumiSonics Inc., a leading company in label-free imaging systems for precision diagnostics, is proud to announce that Jill Stefanelli, PhD has joined the company as an Advisory Board Member and Consultant in Digital and Molecular Pathology.
Dr. Stefanelli brings over 20 years of experience in pathology and molecular diagnostics to the illumiSonics team. A pioneer in precision medicine, she has held positions as President and Chief Business Officer at Paige, where her business leadership was central to the company’s corporate strategy and strong commercial growth. In this role, Jill oversaw strategic partnerships with life science companies and the biomarker development strategy with pharmaceutical partners.
Dr. Stefanelli brings over 20 years of experience in pathology and molecular diagnostics to the illumiSonics team. A pioneer in precision medicine, she has held positions as President and Chief Business Officer at Paige, where her business leadership was central to the company’s corporate strategy and strong commercial growth. In this role, Jill oversaw strategic partnerships with life science companies and the biomarker development strategy with pharmaceutical partners.
Prior to this, she served as Senior Vice President of Partnerships at Invitae, by way of the ArcherDX acquisition, where she led global Companion Diagnostic partnerships with pharmaceutical companies to improve cancer diagnosis and treatment. Previously, she established the first Companion Diagnostic program for the OncomineDX assay at Thermo Fisher Scientific and held roles at Pacific Biosciences, Roche Diagnostics, and the U.S. Department of Agriculture's (USDA) Foreign Animal Disease Laboratory at Plum Island New York.
Dr. Stefanelli’s proven track record of developing and implementing digital pathology solutions, along with her deep understanding of the digital pathology precision medicine market, will be invaluable to illumiSonics. In her new role, Dr. Stefanelli will work closely with illumiSonics' R&D team to help develop and optimize the company's revolutionary PARS platform which virtually stains images, preserving precious tissue and transforming the diagnostic journey with the ultimate promise of curing diseases.
"I am beyond thrilled to join the illumiSonics team," said Jill. "PARS has the potential to revolutionize the field of digital pathology and histology, and I am excited to help bring this technology to market. The ability to generate multiple diagnoses from a single tissue sample has the potential to save lives and reduce costs, and I am honored to be a part of this ground-breaking work."
"We are delighted to have Jill join our team as an Advisor and Consultant in Digital and Molecular Pathology," said Parsin Haji Reza, CTO of illumiSonics Inc. "Her expertise in digital and molecular pathology will be invaluable as we continue to develop and optimize our PARS platform. We are confident that her contributions will help us to achieve our mission of transforming the field of histology and improving patient outcomes."
We look forward to the impact she will have on the company and the field of precision diagnostics.
About illumiSonics Inc.
illumiSonics Inc. is a Waterloo, Ontario company that has developed the PARS platform, a revolutionary non-contact, high-resolution, label-free, non-destructive microscope. PARS captures all light-matter interactions to give unprecedented deep data which is then processed using AI to yield multiple virtual histological stains leading to precision diagnostics. The ability to generate multiple diagnoses from a single tissue sample addresses an unmet medical need that has the potential to save lives and reduce costs. For more information, visit www.illumisonics.com.
Dr. Stefanelli’s proven track record of developing and implementing digital pathology solutions, along with her deep understanding of the digital pathology precision medicine market, will be invaluable to illumiSonics. In her new role, Dr. Stefanelli will work closely with illumiSonics' R&D team to help develop and optimize the company's revolutionary PARS platform which virtually stains images, preserving precious tissue and transforming the diagnostic journey with the ultimate promise of curing diseases.
"I am beyond thrilled to join the illumiSonics team," said Jill. "PARS has the potential to revolutionize the field of digital pathology and histology, and I am excited to help bring this technology to market. The ability to generate multiple diagnoses from a single tissue sample has the potential to save lives and reduce costs, and I am honored to be a part of this ground-breaking work."
"We are delighted to have Jill join our team as an Advisor and Consultant in Digital and Molecular Pathology," said Parsin Haji Reza, CTO of illumiSonics Inc. "Her expertise in digital and molecular pathology will be invaluable as we continue to develop and optimize our PARS platform. We are confident that her contributions will help us to achieve our mission of transforming the field of histology and improving patient outcomes."
We look forward to the impact she will have on the company and the field of precision diagnostics.
About illumiSonics Inc.
illumiSonics Inc. is a Waterloo, Ontario company that has developed the PARS platform, a revolutionary non-contact, high-resolution, label-free, non-destructive microscope. PARS captures all light-matter interactions to give unprecedented deep data which is then processed using AI to yield multiple virtual histological stains leading to precision diagnostics. The ability to generate multiple diagnoses from a single tissue sample addresses an unmet medical need that has the potential to save lives and reduce costs. For more information, visit www.illumisonics.com.
Download Here
| Jill Stefanelli Press Release |